<DOC>
	<DOC>NCT01303380</DOC>
	<brief_summary>This pilot study is designed to evaluate the efficacy, the safety, and the pharmacokinetics (PK) / pharmacodynamics (PD) of canakinumab treatment in patients with HIDS.</brief_summary>
	<brief_title>Canakinumab in Patients With Active Hyper-IgD Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Mevalonate Kinase Deficiency</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Patients with a diagnosis of HIDS proven by DNA analysis and/or enzymatic studies. 2. At time of start of drug treatment: active HIDS as evidenced by a physician global assessment of HIDS flare severity â‰¥ 2 and CRP values &gt;10 mg/L (normal CRP &lt; or = 10 mg/L). 3. Patients who have a history of &gt; or = 3 febrile acute HIDS flares in a 6month period when not receiving prophylaxis treatment (e.g. anakinra daily treatment) with a duration of each flare lasting &gt; or = 4 days and limiting the normal daily activities. 1. Pregnant or nursing (lactating) women. 2. History of being immunocompromised, including a positive HIV at screening (ELISA and Western blot) test result. 3. Positive Hepatitis B or Hepatitis C. 4. Live vaccinations within 3 months prior to the start of the trial 5. Positive tuberculosis screening test. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hyper IgD syndrome</keyword>
	<keyword>canakinumab</keyword>
	<keyword>HIDS</keyword>
	<keyword>mevalonate kinase deficiency</keyword>
	<keyword>MKD</keyword>
</DOC>